Sobi Submits Application for Orfadin to EMA

News
Article

Sobi's application for Orfadin oral suspension has been validated by EMA.

Sobi announced that the company's application for Orfadin oral suspension has been validated by EMA. This new dosage form has been developed to facilitate the accuracy in administration of the desired Orfadin dose to pediatric patients and to increase expediency for the patients and their caregivers.
 
The oral suspension is included in a Paediatric Investigation Plan agreed with EMA in March 2012.

Source: Sobi

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content